keratin-1

MK-886 (L 663536) is an inhibitor of leukotriene biosynthesis, acting by inhibiting the 5-lipoxygenase-activating protein (FLAP), and serves as a moderately potent PPARα antagonist.

KAMP-19 is a keratin-derived antimicrobial peptide with activity against P. aeruginosa. [1]

P160 peptide is a breast cancer-targeting peptide that binds to the keratin 1 (KRT1) receptor in breast cancer cells, with a Kd of approximately 1.1 μM. It shows significant potential for targeted drug delivery to breast cancer cells. P160 peptide enhances the cellular uptake and anticancer activity of the pro-apoptotic antimicrobial peptide MccJ25 (microcin J25). It is applicable in cancer research studies.

Breastcancertargeting peptide 18–4 is a keratin 1 (KRT1) receptor-targeting peptide with a dissociation constant (Kd) of 0.98 μM. Its amino acid sequence is WxEAAYQrFL, and it is an analogue of the P160 peptide. When covalently bonded with the anticancer peptide MccJ25, it significantly enhances MccJ25 uptake in breast cancer cells and boosts its anticancer efficacy. The IC50 values for this covalent compound are 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR, respectively.

Carbohydrate Sulfotransferase 1 (EC:2.8.2.21) catalyzes the transfer of sulfate to the 6-position of galactose (Gal) residues within keratin.